ALNY vs. BMY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and BMY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
BMY stands out with 95.18 billion USD in market value—about 2.49× ALNY’s market cap of 38.15 billion USD.
BMY carries a higher beta at 0.40, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | BMY |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Dr. Christopher S. Boerner Ph.D. |
| Price | 292.58 USD | 46.77 USD |
| Market Cap | 38.15 billion USD | 95.18 billion USD |
| Beta | 0.17 | 0.40 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | June 1, 1972 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and BMY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and BMY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while BMY at 17.53 signals healthy earnings.
- Analysts assign negative forward PEG ratios to both ALNY (-38.16) and BMY (-3.01), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, BMY (P/FCF 7.27) indicates positive free cash flow generation.
| Symbol | ALNY | BMY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 17.53 |
| Forward PEG Ratio (TTM) | -38.16 | -3.01 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 2.00 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 5.46 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 7.27 |
| EV-to-EBITDA (TTM) | -251.73 | 8.38 |
| EV-to-Sales (TTM) | 16.37 | 2.85 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 10.36 |
Dividend Comparison
ALNY offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while BMY provides a 5.22% dividend yield, giving investors a steady income stream.
| Symbol | ALNY | BMY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 5.22% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and BMY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while BMY at 2.95 keeps leverage at a more moderate level.
- With negative EBIT (-0.79), ALNY cannot cover its interest payments. BMY, with an interest coverage of 4.36, meets its interest obligations.
| Symbol | ALNY | BMY |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.28 |
| Quick Ratio (TTM) | 2.98 | 1.17 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 2.95 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.55 |
| Interest Coverage Ratio (TTM) | -0.79 | 4.36 |